Amyris (AMRS) Reports Q1 Loss of $0.13/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amyris Reports 164% Product Revenue Growth over Prior Year & Continued Strong Outlook
May 15, 2017 4:21 PM EDTQ1 2017 revenues of $13.0 million, up 47% over $8.8 million for Q1 2016Q1 2017 product sales of $8.3 million, up 164% over $3.1 million for Q1 2016 with Biossance sales also at a record level powered by successful debut at SEPHORAAnticipated equity financing of up to $95 million from Royal DSM and investors over two tranches and debt reduction of approximately $75 million
EMERYVILLE, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq: AMRS), the industrial bioscience company, today announced financial results for the first quarter ended March 31, 2017.
We are pleased with our continued execution... More
